Ambris 5 Tablet

About Ambris 5 Tablet

Ambris 5 comes as a tablet with 5 mg of Ambrisentan, from Opsonin Pharma Limited. Do not use it for any other condition or share it with others.

There are 4 brands of Ambrisentan listed in Bangladesh.

What is Ambris 5 Tablet?

The tablet Ambris 5 contains Ambrisentan and is made by Opsonin Pharma Limited. Ambris 5 is available as a 5 mg tablet. In pulmonary arterial hypertension, blood pressure in the lung arteries is raised, which makes the heart work harder. Whether it suits a particular person depends on their overall health and other conditions, so the treating doctor decides if it is appropriate.

Uses of Ambris 5

Do not use it for any other condition or share it with others. It helps improve the ability to exercise and delays worsening of the condition. Treatment with Ambrisentan aims to improve how well a person can exercise and to delay the disease getting worse. Your doctor will decide if it is suitable for you.

How to use Ambris 5

The tablet can be taken with or without food. Ambris 5 is taken by mouth. Swallow the tablet with water. Keep the medicine out of reach of children. The dose and how long you take it are decided by your doctor, who will also adjust treatment based on how you respond and tolerate it. Do not change the dose yourself.

Side effects of Ambris 5

If you develop sudden shortness of breath or swelling that gets worse, contact your doctor promptly. Some people may notice side effects while taking Ambrisentan. Your doctor may arrange blood tests during treatment. Tell your doctor if any side effect bothers you or does not go away. Tell your doctor about any new or unusual symptoms.

Safety and precautions

Breastfeeding is not recommended while taking it. Ambris 5 must not be used during pregnancy, and pregnancy should be ruled out before starting it and prevented during treatment and for a period after stopping. Swelling and sudden breathlessness during treatment need medical attention. Tell your doctor if you are pregnant, planning a pregnancy or breastfeeding.

Frequently asked questions

What is Ambris 5 used for?

Do not use it for any other condition or share it with others. It helps improve the ability to exercise and delays worsening of the condition.

How is Ambris 5 used?

The tablet can be taken with or without food. Ambris 5 is taken by mouth.

What are the side effects of Ambris 5?

If you develop sudden shortness of breath or swelling that gets worse, contact your doctor promptly. Some people may notice side effects while taking Ambrisentan.

Is Ambris 5 safe for everyone?

Breastfeeding is not recommended while taking it. Ambris 5 must not be used during pregnancy, and pregnancy should be ruled out before starting it and prevented during treatment and for a period after stopping.

Indications

Ambrisentan is indicated for the treatment of Pulmonary Arterial Hypertension (PAH) (WHO Group 1) to improve exercise ability and delay clinical worsening.

Pharmacology

Endothelin-1 (ET-1) is a potent autocrine and paracrine peptide. Two receptor subtypes, ETA and ETB, mediate the effects of ET-1 in the vascular smooth muscle and endothelium. The primary actions of ETA are vasoconstriction and cell proliferation, while the predominant actions of ETB are vasodilation, antiproliferation, and ET-1 clearance. Ambrisentan is a high-affinity ETA receptor antagonist with a high selectivity for the ETA versus ETB receptor (>4000-fold). The clinical impact of high selectivity for ETA is not known.

The pharmacokinetics of Ambrisentan (S-Ambrisentan) in healthy subjects are dose proportional. The absolute bioavailability of Ambrisentan is not known. Ambrisentan is absorbed with peak concentrations occurring approximately 2 hours after oral administration in healthy subjects and PAH patients. Food does not affect its bioavailability. In vitro studies indicate that Ambrisentan is a substrate of P-gp. Ambrisentan is highly bound to plasma proteins (99%). The elimination of Ambrisentan is predominantly by non-renal pathways, but the relative contributions of metabolism and biliary elimination have not been well characterized. In plasma, the AUC of 4-hydroxymethyl Ambrisentan accounts for approximately 4% relative to parent Ambrisentan AUC. Thein vivo inversion of S-Ambrisentan to R-Ambrisentan is negligible. The mean oral clearance of Ambrisentan is 38 mL/min and 19 mL/min in healthy subjects and in PAH patients, respectively. Although Ambrisentan has a 15-hour terminal half-life, the mean trough concentration of Ambrisentan at steady-state is about 15% of the mean peak concentration and the accumulation factor is about 1.2 after long-term daily dosing, indicating that the effective half-life of Ambrisentan is about 9 hours.

Dosage & Administration

Adult dose: Initial treatment is 5 mg once daily, and can be increased to 10 mg once daily if 5 mg is tolerated. Ambrisentan may be administered with or without food.

Pediatric patients: The safety and effectiveness of Ambrisentan in pediatric patients have not been established.

Interaction

Multiple dose co-administration of Ambrisentan and Cyclosporine resulted in an approximately 2-fold increase in Ambrisentan exposure in healthy volunteers; therefore, limit the dose of Ambrisentan to 5 mg once daily when co-administered with Cyclosporine.

Contraindications

Ambrisentan may cause fetal harm when administered to a pregnant woman. Ambrisentan is contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus. Pregnancy must be excluded before the initiation of treatment with Ambrisentan and prevented during treatment and for one month after stopping treatment. Ambrisentan is contraindicated in patients with Idiopathic Pulmonary Fibrosis (IPF) including IPF patients with pulmonary hypertension (WHO Group 3).

Side Effects

Decreases in hemoglobin concentration and hematocrit have followed administration of other endothelin receptor antagonists and were observed in clinical studies with Ambrisentan

Pregnancy & Lactation

Pregnancy Category X. It is not known whether Ambrisentan is excreted in human milk. Breastfeeding while receiving Ambrisentan is not recommended.

Precautions & Warnings

Fluid Retention: Peripheral edema is a known class effect of endothelin receptor antagonists, and is also a clinical consequence of PAH and worsening PAH.

Pulmonary Veno-occlusive Disease: If patients develop acute pulmonary edema during initiation of therapy with vasodilating agents such as Ambrisentan, the possibility of pulmonary veno-occlusive disease should be considered, and if con_rmed. Ambrisentan should be discontinued.

Hematological Changes: Decreases in hemoglobin concentration and hematocrit have followed administration of other endothelin receptor antagonists and were observed in clinical studies with Ambrisentan.

Hepatic impairment: Ambrisentan is not recommended in patients with moderate or severe hepatic impairment.

Storage Conditions

Store in a cool and dry place, below 30°C. Protect from light and moisture.

Alternative brands of Ambrisentan

Other brands with the same generic name, cheapest first.

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.